Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study
BioDrugs · 2024
DOI: 10.1007/s40259-024-00681-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BioDrugs, 2024. Verfasst von Guillaume Bouguen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Rennes University Hospital, Rennes University, INSERM, CIC1414, NUMECAN (Nutrition Metabolism and Cancer) Institute, Rennes, France. Hauptthemen laut MEDLINE: Adalimumab, Biosimilar Pharmaceuticals, Patient Satisfaction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rennes University Hospital, Rennes University, INSERM, CIC1414, NUMECAN (Nutrition Metabolism and Cancer) Institute, Rennes, France.
- Sorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.
- Department of Rheumatology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
- Department of Gastroenterology, Cochin University Hospital, AP-HP, Université Paris Cité, Paris, France.
- Medical practice, Marseille, France.
- Department of Rheumatology, Ste Marguerite University Hospital, Marseille, France.
Zitieren
APA
Bouguen, G., Gossec, L., Abitbol, V., Senbel, E., Bonnaud, G., Roblin, X., Bouhnik, Y., Nancey, S., Mathieu, N., Filippi, J., Vuitton, L., Nahon, S., Dellal, A., Denis, A., Foulley, L., Habauzit, C., Benkhalifa, S., & Marotte, H. (2024). Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study. BioDrugs. https://doi.org/10.1007/s40259-024-00681-2
Vancouver
Bouguen G, Gossec L, Abitbol V, Senbel E, Bonnaud G, Roblin X, et al. Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study. BioDrugs. 2024. doi:10.1007/s40259-024-00681-2
BibTeX
@article{Bouguen2024,
author = {Bouguen, Guillaume and Gossec, Laure and Abitbol, Vered and Senbel, Eric and Bonnaud, Guillaume and Roblin, Xavier and Bouhnik, Yoram and Nancey, Stéphane and Mathieu, Nicolas and Filippi, Jérôme and Vuitton, Lucine and Nahon, Stéphane and Dellal, Azeddine and Denis, Alice and Foulley, Lucile and Habauzit, Caroline and Benkhalifa, Salim and Marotte, Hubert},
title = {Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study},
journal = {BioDrugs},
year = {2024},
doi = {10.1007/s40259-024-00681-2}
}
EUVIMED